Study of Safety, Tolerability and Efficacy of MK0493 in Obese Patients (0493-008)(COMPLETED)

Merck Sharp & Dohme (MSD)

Status and phase

Completed

Phase 2

Conditions

Obesity

Treatments

Drug: MK0493

Study type

Interventional

Funder types

Industry

Identifiers

0493-008

2007_571

Details and patient eligibility

About

To assess the effect of MK0493 on body weight, blood pressure, mood, and appetite.

Sex

All

Ages

21 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patient is between 21 and 65 years
Patient is able to read and understand and complete study questionnaires
Patient is not pregnant or breast-feeding and does not plan to become pregnant for the duration of the study and post-study follow-up period

Exclusion criteria

Patient has a history of significant psychiatric disorder (such as major depression, bipolar disorder, bulimia, or anorexia nervosa
Patient is HIV positive as determined by medical history
Patient has undergone surgical treatment for obesity
Patient plans to consume more than two 8 ounce glasses of grapefruit juice per day during the study
Patient participated in another clinical study involving an investigational drug) within 3 months prior to Visit 1
Patient is currently a heavy consumer of alcohol (>2 drinks per day or >14 drinks per week [1 drink is defined as 2 oz hard alcohol, 5 oz wine, 12 oz beer], or uses (including recreational use) any illicit drugs, or has a history of drug or alcohol abuse